EC Number   |
Expression |
Reference |
|---|
    1.14.14.23 | down |
activation of an AMP-activated protein kinase decreases CYP7A1 mRNA, hepatocyte nuclear factor 4alpha protein, and binding to CYP7A1 chromatin |
712678 |
| 1.14.14.23 | down |
bile acid-activated farnesoid X receptor, FXR, inhibits CYP7A1 transcription via activation of FGF15 receptor 4 signaling in hepatocytes, or via FGF19, that strongly inhibits CYP7A1 mRNA expression, overview. miR-122a and miR-422a may destabilize CYP7A1 mRNA to inhibit CYP7A1 expression, putative recognition sequences for miR-122a and miR-422a are localized in the 3'-UTR of human CYP7A1 mRNA |
712675 |
| 1.14.14.23 | down |
Chlamydia pneumoniae and human cytomegalovirus infections significantly decrease isoform CYP7A1 promoter activity in a dose-dependent manner, with maximal inhibitions of 33% and 32%, respectively |
723941 |
| 1.14.14.23 | down |
CYP7A1 protein expression in chronic hypothyroid rats is significantly decreased |
700572 |
| 1.14.14.23 | down |
expression is strongly repressed after 70% partial hepatectomy (during liver regeneration) |
700216 |
| 1.14.14.23 | down |
several negative feedback loops within the liver and small intestine down-regulate Cyp7a1 transcription to prevent accumulation of bile acids to toxic levels. The the JNK/c-Jun pathway is involved in downregulation of Cyp7a1, overview |
712117 |
| 1.14.14.23 | down |
several nutritive peptides inhibit luciferase expression (cyp7alpha-reporter gene (promoter fragment fused to firefly luciferase)) |
698408 |
| 1.14.14.23 | more |
CYP7A1 mRNAs have very short half-lives, and bile acids destabilize CYP7A1 mRNA via the 3'-untranslated region |
712675 |
| 1.14.14.23 | more |
fibroblast growth factor 19 inhibits cholesterol 7alpha-hydroxylase mRNA expression |
698159 |
| 1.14.14.23 | more |
Forkhead box transcription factor O1 inhibits cholesterol 7alpha-hydroxylase mRNA expression |
696446 |
